Omeros Co. (NASDAQ:OMER) VP Michael A. Jacobsen sold 1,020 shares of the firm’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $22.45, for a total value of $22,899.00. Following the completion of the sale, the vice president now directly owns 8,520 shares of the company’s stock, valued at $191,274. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Omeros Co. (OMER) traded down $0.28 during midday trading on Friday, hitting $19.42. The stock had a trading volume of 374,228 shares, compared to its average volume of 646,610. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77. Omeros Co. has a 12-month low of $8.71 and a 12-month high of $27.09. The stock has a market capitalization of $932.23, a P/E ratio of -15.05 and a beta of 3.56.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.18. The business had revenue of $21.66 million during the quarter, compared to analysts’ expectations of $17.82 million. During the same quarter in the previous year, the company posted ($0.34) earnings per share. The company’s quarterly revenue was up 91.9% compared to the same quarter last year. research analysts expect that Omeros Co. will post -0.98 EPS for the current year.

Several equities research analysts have recently issued reports on OMER shares. Cowen lowered Omeros from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 2nd. Maxim Group set a $24.00 price target on Omeros and gave the stock a “buy” rating in a report on Friday, October 20th. Zacks Investment Research upgraded Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. HC Wainwright started coverage on Omeros in a report on Wednesday, November 8th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $47.00 price target on shares of Omeros in a report on Tuesday, November 28th. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Omeros presently has a consensus rating of “Buy” and an average price target of $34.14.

Hedge funds and other institutional investors have recently modified their holdings of the company. First Interstate Bank purchased a new position in Omeros during the 3rd quarter worth $108,000. Legal & General Group Plc increased its holdings in Omeros by 7.8% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 751 shares during the period. Hanseatic Management Services Inc. increased its holdings in Omeros by 10,919.6% during the 3rd quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 10,592 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new position in Omeros during the 3rd quarter worth $256,000. Finally, SG Americas Securities LLC increased its holdings in Omeros by 138.9% during the 3rd quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock worth $263,000 after purchasing an additional 7,067 shares during the period. Hedge funds and other institutional investors own 49.71% of the company’s stock.

WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/05/insider-selling-omeros-co-omer-vp-sells-1020-shares-of-stock.html.

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.